Oseltamivir Injection (IV Formulation)
Oseltamivir is best known as the oral antiviral Tamiflu® (capsule or liquid) used to treat and prevent influenza A and B. In a few countries a parenteral (intravenous) formulation—oseltamivir phosphate injection—is available for patients who cannot take oral medication. It is rarely stocked in the United States and is mainly used in Japan, China, Korea, and some other Asian markets.
---
1. What Is It?
| Feature | Oral | IV |
|---------|------|----|
| Drug | Oseltamivir carboxylate (the active metabolite) | Oseltamivir phosphate (prodrug that rapidly converts to the active metabolite) |
| Indications | • Symptomatic treatment of uncomplicated influenza (within 48 h of symptom onset)
• Post‑exposure prophylaxis (PEP) for close contacts of an influenza case | • Treatment of severe influenza when oral intake is impossible or unreliable (e.g., intubated, vomiting, unconscious)
• PEP in patients who cannot take oral medication |
| Availability | Widely available worldwide (oral capsules and liquid) | Limited to a handful of countries; not marketed in the U.S. or EU for IV use |
---
2. How Is It Administered?
* Reconstitution – The lyophilized powder is mixed with sterile water (or 5 % dextrose) to a final concentration of 10 mg/mL.
* Infusion – Typically given as a 30‑minute IV infusion.
* Dosing schedule – Two‑dose daily schedule (morning + evening).
---
3. Dosage (Based on the FDA and EMA package inserts)
NOTE: Always refer to the local product insert or clinical guidelines for the most current recommendations; the following is a general reference.
| Population | Treatment | Prophylaxis |
|------------|-----------|--------------|
| Adults | 10 mg/kg/day (max 400 mg/day) – split into two divided doses for 5 days | 2 mg/kg/day (max 200 mg/day) – split into two divided doses for 10–14 days |
| Children | 5 mg/kg/day (max 200 mg/day) – split into two divided doses for 5 days | 2 mg/kg/day – split into two divided doses for 10–14 days |
Examples
• 70‑kg adult → 700 mg/day (≈ 350 mg each dose)
• 15‑kg child → 75 mg/day (≈ 37.5 mg each dose)
---
4. Pharmacology
* Mechanism of Action – Oseltamivir is a neuraminidase inhibitor; it blocks the viral enzyme that cleaves sialic acid, preventing release of new virions from infected cells.
* Metabolism – Rapidly dephosphorylated in the liver to the active carboxylate form.
* Half‑life – ~10 h for the active metabolite.
* Excretion – Primarily renal (≈ 90 % unchanged metabolite).
---
5. Safety & Side Effects
| Category | Common | Rare | Serious |
|----------|--------|------|---------|
| Common | Nausea, vomiting, headache, mild rash | | |
| Rare | Dizziness, fatigue, diarrhea | | |
| Serious | Allergic reactions (rash, urticaria, anaphylaxis), hypersensitivity pneumonitis | | |
* Renal impairment – Dose adjustment is usually not required for the IV formulation, but monitor renal function.
* Pregnancy – Category C; use only if benefit outweighs risk.
* Lactation – No contraindication; drug is excreted in breast milk in low amounts.
---
6. Contraindications & Precautions
| Condition | Recommendation |
|-----------|----------------|
| Known hypersensitivity to oseltamivir or any excipient (e.g., magnesium stearate, gelatin) | Contraindicated |
| Severe immunosuppression (e.g., neutropenia) | Use cautiously; monitor closely |
| Recent influenza vaccination | No interaction; no need to adjust dose |
---
7. Drug Interactions
* None clinically significant – Oseltamivir is not metabolized by major CYP450 enzymes.
* Concurrent use with other antivirals (e.g., zanamivir) is not recommended without specialist guidance.
---
8. Practical Tips for Clinicians
1. Confirm diagnosis – Viral culture, rapid antigen, or PCR if available; IV oseltamivir is usually reserved for confirmed or highly suspected severe cases.
2. Start early – Ideally within 48 h of symptom onset for maximum benefit.
3. Monitor for side effects – Especially in patients with pre‑existing allergies or respiratory distress.
4. Document – Record weight, dosing, infusion time, and any adverse events.
5. Plan for transition – If the patient recovers, consider switching to oral therapy once they can swallow.
---
9. Where to Find It
* Japan – Tamiflu® IV is marketed by Roche (or its local partner).
* China & South Korea – Similar products are available through local manufacturers.
* U.S. & EU – Only the oral formulation is approved; the IV version is not licensed for use.
---
Bottom Line
Oseltamivir injection is a valuable rescue option for patients who cannot take oral medication due to severe illness, vomiting, or unconsciousness. Its dosing is weight‑based, and it is generally well tolerated. If you’re caring for a patient in a region where IV oseltamivir is available, use the dosing tables above and monitor for allergic reactions. Always verify local regulatory status and